CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-07-11 | Quinn Anthony G. Interim CEO | Option exercise · Director Stock Option (right to buy) | −3,307 | 5,291 | ||
| 2018-06-07 | Shanafelt Armen Director | Grant or award · Director Stock Option (right to buy) | +18,400 | 18,400 | ||
| 2018-06-07 | Mahatme Sandesh Director | Grant or award · Director Stock Option (right to buy) | +18,400 | 18,400 | ||
| 2018-06-07 | GEORGIOU GEORGE Director | Grant or award · Director Stock Option (right to buy) | +18,400 | 18,400 | ||
| 2018-06-07 | Cox Russell J. Director | Grant or award · Director Stock Option (right to buy) | +18,400 | 18,400 | ||
| 2018-06-07 | Bruhn Suzanne Louise Director | Grant or award · Director Stock Option (right to buy) | +18,400 | 18,400 | ||
| 2018-05-11 | Novartis Bioventures Ltd 10% owner | Sale | −19,550 | $10.06 | $197K | 2,175,314 |
| 2018-05-10 | Novartis Bioventures Ltd 10% owner | Sale | −22,725 | $10.13 | $230K | 2,194,864 |
| 2018-05-09 | Novartis Bioventures Ltd 10% owner | Sale | −51,230 | $10.11 | $518K | 2,217,589 |
| 2018-05-08 | Novartis Bioventures Ltd 10% owner | Sale | −26,557 | $10.03 | $266K | 2,268,819 |
| 2018-05-07 | Novartis Bioventures Ltd 10% owner | Sale | −15,548 | $10.11 | $157K | 2,295,376 |
| 2018-03-22 | Magovcevic Ivana Director | Grant or award · Director Stock Option (right to buy) | +36,800 | 36,800 | ||
| 2018-02-20 | Wooldridge James Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-02-20 | York Charles N II Chief Financial Officer and VP | Grant or award · Employee Stock Option (right to buy) | +92,100 | 92,100 | ||
| 2018-02-20 | Quinn Anthony G. Interim CEO | Grant or award · Employee Stock Option (right to buy) | +178,400 | 178,400 | ||
| 2018-02-20 | Schuchart Aaron Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2018-02-15 | Quinn Anthony G. President & CEO | Purchase | +2,000 | $6.02 | $12K | 94,793 |
| 2018-02-15 | Quinn Anthony G. Interim CEO | Option exercise | +15,211 | $5.46 | $83K | 50,620 |
| 2018-02-15 | Quinn Anthony G. Interim CEO | Option exercise · Director Stock Option (right to buy) | −15,211 | 8,598 | ||
| 2017-12-08 | Quinn Anthony G. Interim CEO | Purchase | +600 | $5.07 | $3K | 35,409 |
Page 17 of 19 · 372 trades